Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

By afschroeder • August 13, 2025

van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits J, Drakaki A, Mar N, Maroto Rey JP, Vulsteke C, Arafat W, Duran I, Dawson NA, Swami U, Gorla S, Moreno BH, Yu X, Lu YT, Bedke J. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025 Aug 11;10(8):105544. doi: 10.1016/j.esmoop.2025.105544. Epub ahead of print. PMID: 40795788.

Tags: Bladder cancer, enfortumab vedotin, Hematology/Oncology, metastatic urothelial carcinoma, pembrolizumab, Phase III, Publications, subgroup analysis

Related Posts

ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer

Collier AE, Hilz S, Chibly AM, Duan C, Pasquina LW, Sun X, Chavez-MacGregor M, Bardia A, Martín M, Lim E, Sohn J, Pérez-Moreno PD, Fernando[...]

Lentivirus-Based Hematopoietic Stem/Progenitor Cell Therapy Provides Effective and Long-Term Treatment in Hypophosphatasia Mouse Model

Carrillo M, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine[...]

Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival

Marsh LA, Kim TH, Zhang M, Kubalanza K, Treece CL, Chase D, Memarzadeh S, Salani R, Karlan B, Rao J, Konecny GE. Pathologic response to[...]